Bioventix PLC
BVXP
Company Profile
Business description
Bioventix PLC is a biotechnology company based in the United Kingdom. It specializes in the creation and supply of high-affinity sheep monoclonal antibodies and clinical diagnostics and drug abuse testing. The company's portfolio of products includes drugs that are applicable in the areas of cardiology, fertility, infectious diseases, Thyroid, and vitamin D disorder among others. It earns maximum revenue from European country.
Contact
27-28 Eastcastle Street
LondonW1W 8DH
GBRSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
16
Stocks News & Analysis
stocks
The best way to get rich and retire early
This goes through the different options including shares, property and business ownership and declares a winner, as well as outlining the mindset needed to earn enough to never have to work again.
stocks
Investors overly negative on cheap ASX share
We cut our fair value by 26% but the market has overreacted.
stocks
Overvalued US AI play reports earnings
Strong earnings with high projected growth but price is too rich.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,035.50 | 16.90 | 0.19% |
| CAC 40 | 8,121.07 | 0.00 | 0.00% |
| DAX 40 | 24,283.97 | 4.43 | -0.02% |
| Dow JONES (US) | 48,362.68 | 227.79 | 0.47% |
| FTSE 100 | 9,865.97 | 31.45 | -0.32% |
| HKSE | 25,801.77 | 111.24 | 0.43% |
| NASDAQ | 23,428.83 | 121.21 | 0.52% |
| Nikkei 225 | 50,485.11 | 82.72 | 0.16% |
| NZX 50 Index | 13,509.63 | 1.33 | 0.01% |
| S&P 500 | 6,878.49 | 43.99 | 0.64% |
| S&P/ASX 200 | 8,735.90 | 19.00 | 0.22% |
| SSE Composite Index | 3,917.36 | 26.92 | 0.69% |